TW200803760A - Nutritional formulation for promoting catch-up growth - Google Patents
Nutritional formulation for promoting catch-up growth Download PDFInfo
- Publication number
- TW200803760A TW200803760A TW095137247A TW95137247A TW200803760A TW 200803760 A TW200803760 A TW 200803760A TW 095137247 A TW095137247 A TW 095137247A TW 95137247 A TW95137247 A TW 95137247A TW 200803760 A TW200803760 A TW 200803760A
- Authority
- TW
- Taiwan
- Prior art keywords
- formulation
- pufa
- probiotic
- amount
- growth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 238000009472 formulation Methods 0.000 title claims abstract description 36
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 20
- 230000001737 promoting effect Effects 0.000 title claims description 7
- 239000006041 probiotic Substances 0.000 claims abstract description 25
- 235000018291 probiotics Nutrition 0.000 claims abstract description 25
- 230000000529 probiotic effect Effects 0.000 claims abstract description 23
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 21
- 241000124008 Mammalia Species 0.000 claims abstract description 19
- 239000000835 fiber Substances 0.000 claims abstract description 15
- 230000001580 bacterial effect Effects 0.000 claims abstract description 12
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- 229920001202 Inulin Polymers 0.000 claims description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 11
- 229940029339 inulin Drugs 0.000 claims description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 7
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 7
- 229920000084 Gum arabic Polymers 0.000 claims description 6
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 6
- 239000000205 acacia gum Substances 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 2
- 241000978776 Senegalia senegal Species 0.000 claims 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 11
- 230000003340 mental effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 235000013350 formula milk Nutrition 0.000 description 23
- 235000005911 diet Nutrition 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 230000037213 diet Effects 0.000 description 19
- 239000000843 powder Substances 0.000 description 11
- 239000003925 fat Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 239000013589 supplement Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000153 supplemental effect Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- 235000020940 control diet Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000000366 juvenile effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- -1 xylose oligosaccharide Chemical class 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000001488 Bothrioplana sinensis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200803760 九、發明說明: 【發明所屬之技術領域】 本發明係關於用於促進因經受身體或精神緊迫而使成長 遲緩之幼年哺乳動物趕上成長進度之配方及該等配方之用 途,特言之,本發明係關於含有用於促進趕上成長進度之 成分之增效組合的配方。 【先前技術】 a夕年來直6忍為’遭受緊迫幼年哺乳動物的成長模式通 吊曰又阻不&其係因身體之疾病或傷害或心裏創傷所致 之緊k力幼年哺乳動物可快速恢復且獲得《足營養,則 其可趕上在緊迫期間原本應有之成長進度,此突發之成長 被稱為’’趕上成長進度之成長”。然而,此情況並非總能發 生。舉例而言’幼年哺乳動物在疾病或創傷期間及隨即在 事鶴產生厭食’因此可食物攝取量可能有限。情況嚴 重日守,動物可能再也無法達到其若未經受緊迫所可達到之 甘此現象可見於幼年哺乳動物(包括人類),自幼兒期貫穿 緊希望確保能趕上在身體或精神 、 ' 又仁趕上成長進度亦不應過度乃重要 声因:有跡象顯示,極為快速及/或極為過度趕上成長 期’可能與未來肥胖之風險有關,尤其 内發生的話。 凡^ 因此,本發明之目 緊迫之幼年哺乳動物 的在於提供適於促進遭受身體 之最佳趕上成長進度的配方。 或精神 115048.doc 200803760 【發明内容】 在本發明之研究期間,發明人意外地觀察到施用特定之 成分組合可促進遭受緊迫之幼年哺乳動物趕上成長進度。 因此’本發明首先提供一種促進趕上成長進度之營養配 方’其包含含有脂肪酸之脂質源、存在組合物中之脂肪酸 之至少0.01%之量的n3長鏈多元不飽和脂肪酸(LC_ PUFA)、每克配方至少心001克之量的益生纖維及每克配方 l〇3-l〇n細胞形成單位(cfu)之量的益生細菌菌株。 本發明其次提供n3長鏈多元不飽和脂肪酸(lc-PUFA)、 益生纖維及盈生細囷函株用於製造供促進患病及恢復期幼 年哺乳動物趕上成長進度之營養配方或藥物的用途。 本發明另外提供一種促進患病或恢復期幼年哺乳動物趕 上成長進度之方法,該方法包括將治療量之包含d PUFA、益生纖維及益生細菌菌株的配方投予有需要之幼 年哺乳動物。 本發明之優點在於其提供不施用合成激素而使用食品級 成分之增效組合來促進趕上成長進度的可能性。此外,受 迫幼年哺乳動物常會厭食,且不願意或不能消耗大量卡路 里;本發明之優點在於提供促進趕上成長進度之機會,而 不增加卡路里攝取量,使身體之精肉及脂肪量平衡,而不 造成肥胖。 【實施方式】 在本說明書中,以下術語具有下文所指定之含義·· _ π益生細菌菌株”意謂藉由改良宿主動物腸内微生物平衡 115048.doc 200803760 而對宿主動物產生有益影響之活微生物食物添加劑(具 ’’Probiotics in Man and Animals' J· Appl Bacteriol. 66: 365-378, 1989) 〇 S生素思明精由選擇性刺激結腸中一種或有限數目細 菌之成長及/或活動而對宿主產生有益影響且因此改良宿 主健康之不易消化的食物成分(自"Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of
Prebiotics",J.Nutr· 125M401 - 1412, 1995) 〇 ’’幼年哺乳動物n意謂包括自出生至所涉及種類之哺乳動 物達到完全體格之年齡的人類及相伴動物之任何哺乳動 物。 盈生細函囷株較佳為乳桿菌屬(Lactobacillus)或雙歧桿 菌屬(Bifidobacterium)菌株。合適乳桿菌屬菌株包括可自
Valio OY(Finland)獲得之鼠李糖乳酸桿菌 rh則〇sw)ATCC 53 103及副乾酪乳桿菌 praaa/)CNCM 1-2116,其中後者尤其較佳。合適雙歧桿 菌屬菌株包括可自Morinaga(Japan)獲得之長雙枝桿菌 {Bifidobacterium /⑽客謂)BB536 、可 自 Christian
Hansen(Denmark)以Bbl2商標獲得之比非德氏菌 (βζ/zWohci⑺·以所/以出)及比非德氏菌CNCM 1-3446。可使 用菌株之組合,其中乳桿菌與雙歧桿菌之組合尤其較佳。 配方中可包括藉由冷凍乾燥或喷霧乾燥獲得之粉末形式的 所選函株。或者’營養配方可另外包含諸如牛奶或縠類之 可酸酵食物,且益生細菌菌株可用以使食物醱酵。 115048.doc 200803760 1生,截、准可遥自果募醣、半乳募醣、涎寡醣、木糖寡 醣、菊糖、阿拉伯膠、瓜爾膠、抗性殿粉、牛奶衍生之寡 聽及其混合物。較佳益生纖維為果s醣、菊糖、阿拉伯膠 及半乳_,尤其為7〇至95%半乳寡醣錢至5%果寡釀與 40至60%阿拉”、戰術。果寡醣及心观菊糖之混 合物。合適半乳寡醣為B〇rcul〇 D〇m〇 IngredientsUVivinai GOS 10商才不所售之半乳养醣。纟適果$醣為〇rafti SA以 Raftilose P95商標所售之果募醣。合適菊糖為〇ram s a以 Raftiline HP商標所售之菊糖。合適阿拉伯膠為^见以
FiberGum P商標所售之阿拉伯膠。益生纖維之存在總量較 佳為配方之0.02- 〇.〇5 g/g。 配方含有至少一種n-3 LC-PUFA,諸如C20或C22 n-3脂 肪酸。C20或C22 n-3 LC-PUFA之存在量較佳為在配方中所 有脂肪酸之至少^丨重量%。n-3 LC-PUFA較佳為二十二碳 六烯酸(DHA,C22:6,n-3)。 配方較佳亦含有n_6多元不飽和脂肪酸,諸如c2〇或C22 n-6脂肪酸。合適n_6 LC_puFA為二十碳四烯酸(AA,C2〇:4 n-6)。C20或C22 n-6 LC-PUFA之存在量較佳為配方中所有 脂肪酸之至少0 · 1重量%。 n6:n3之比較佳介於1:2與8:1之間,更佳介於4:;[與8:1之 間。舉例而言,LC-PUFA之來源可為卵磷脂、真菌油、低 E P A魚油或海藻油。 配方可呈營養增補劑形式,或其可提供完全營養。根據 本發明之營養配方之合適基質的實例為牛奶、酸奶、凝 115048.doc 200803760 乳、奶°酸酵牛奶及牛奶製品、潑酵穀類基製品、牛奶 基粉末、用於Π服及f飼之嬰兒配方及組合物。 在-較佳實施例中,本發明提供嬰兒配方或兒科營養配 方。除上述成分之增效組合之外’其亦可包含蛋白源及/ 或碳水化合物源。 蛋白源可為任何合適腾食蛋白,例 > 動物蛋白(諸如牛 奶蛋白、肉蛋白、蛋蛋白)、植物蛋白(諸如大豆、小麥、 水稻或m蛋自)、游離胺基酸之混合物或其組合。諸如 路蛋白及乳清之牛奶蛋白尤其較佳。在一兒科配方之較佳 實施例中,蛋白源提供組合物之7至14%之能量。 對T兒科配方而言,脂質源較佳提供配方之30%至50% 之症罝。構成脂質源之脂質可為任何合適脂肪或脂肪混合 物。植物脂肪尤其合適’例如大豆油、棕櫚油、椰子油、 紅花油、向日蔡油、玉米油、芬花軒油、印磷脂及類似脂 肪。必要時’亦可添加諸如乳脂之動物脂肪。較佳地,脂 肪源包括至少15%中長鏈三甘油酸醋,且脂肪酸構成為20 至40%飽和脂肪酸、45 $ fin。/ 口口 γ μ < ^ 至60/。早不飽和脂肪酸及10至25% 多元不飽和脂肪酸。 若兒科配方包㈣水化合物源’則碳水化合物源較佳提 供配方之40%至60%之能量。可使用任何合適之碳水化合 物或碳水化合物混合物’例如嚴*、乳糖、葡萄糖、果 糖、玉米漿固形物及麥芽糊精。 、合適維生素及礦物質可以通常方式包括於配方中以適於 適當準則。必要時,—或多種食品級乳化劑可倂入配方 115048.doc 10 200803760 产例如單甘油二酯、卵磷脂及單甘油酯及二甘油酯之二 乙基-酒石酸酯。可包括相似之合適鹽及穩定劑。 二例而s,配方較佳呈用於以水復水之粉末形式可經腸 投復水配方可口服投藥或藉由鼻胃管投藥。其可:任 何合適方式製備,例如藉由以適當比例摻合腾食蛋白源、 碳水化合物源及脂肪源。使用時,乳化劑可包括於摻合物 中:此時可添加維生素及礦物質,但通常稍後添加以避免 熱降解。可將任何親脂性維生素、乳化劑及其類似物在換 合之前溶解於脂肪源中。接著可混入水(較佳為經反滲透 之水)以形成液體混合物。水溫便利地為約5(rc至約8〇。〇以 有助於成刀分散。可使用市售液化劑以形成液體混合物。 舉例而s,接著分兩階段使液體混合物勻質化。 液體混合物接著可經熱處理以減少細菌負荷。舉例而 言,可快速將液體混合物加熱至約80。〇至約15〇t之範圍 :之溫度,歷時約5秒至約5分鐘。此舉可藉由蒸汽注入、 高壓滅菌器或藉由熱交換器(例如板式熱交換器)進行。舉 例而言’接著可藉由急驟冷卻月字液體混合物冷卻至約贼 至約机。舉例而|,可分兩階段:第—階段於約7胳 至約40 Mpa及第二階段於約2 Mpa至約ΐ4 Μρ&再次使液體 混合物句質化。接著可進一步冷卻經句質化之混合物以添 加任何熱敏組份,諸如維生素及礦物f。此時便利地使經 勻λ化之混合物的pH值及固體含量符合標準。 將經勻質化之混合物轉移至諸如噴霧乾燥器或;東乾哭之 合適乾燥設備中’且轉化成粉末。粉末應具有小於約5重 115048.doc 11 200803760 量。/。之含水量。此時可便利地藉由乾燥混合來添 菌菌株。 王、、,田 若需要製造液體配方時,則較佳在無菌條件下將經勾所 化之混合物填充至合適容器中。可藉由預加熱經勾質化: 混合物(例如加熱至約75至85。〇接著將蒸汽注入經句質化 之混合物中以將溫度升高至約140至16rc (例如約150。〇來 進:容器之無g填充。舉例而言’接著藉由急驟冷卻將經 勻質化之混合物冷卻至約75至85。。之溫度。接著可使經勻 質化之此口物勻質丨’進一步冷卻至約室溫且填充入容器 中。用於進行無菌填充、具有此性質之合適設備為市售°。 液體配方可呈具有約10至約14重量%之固體含量之即傲食 方形式或可呈具有約20至約26重量。/❶之固體含量之濃 縮物形式。可向液體配方中添加調味劑。在液體配方之情 況下’較佳將益生細菌菌株單獨封裝以在液體配方消耗前 即刻混合。 幼年哺乳動物所需健食之配方量將隨諸如患者病況、體 重及^齡之因素而變化,不管配方是否為唯_營養源。通 常投藥足夠量之配方,以提供患者每天每公斤體重丨至4公 克補充有上述量之根據本發明之成分的蛋白。若營養配方 用作其他食物之添加劑,則可相應地減少每曰投藥的營養
配方之量。IT 下非限制性實例進一步說明本發明。 實例1 、下、、σ出根據本發明之兒科營養配方之組合物的實例。 此組合物僅為說明之用。 115048.doc -12- 200803760 該配方具有以下組合物(每100 g粉末)··總脂肪18·3 g、 總蛋白13.9 g、總碳水化合物59.2 g、AA營養強化油(真菌 油)〇·2 g、DHA營養強化油(低EPA魚油)〇·2 g、阿拉伯膠 /FOS/菊糖(51%/34%/15%)12 g、副乾酪乳桿菌 CNCM I-2116(Nestl6,噴霧乾燥粉末,l〇E12 cfu/g)〇.l g、長雙枝 桿菌BB536(Morinaga,噴霧乾燥粉末,5χ10Ε12 cfu/g)0.1g、鈉 222 mg、鉀 500 mg、氯化物 370 mg、磷 278 mg、妈 417 mg、鎂 53 mg、猛 231 pg、維生素 A 680 IU、 維生素D 180 IU、維生素E 6.8 IU、維生素C 36 mg、維生 素 K1 18 pg、維生素 B1 0.27 mg、維生素 B2 0.36 mg、維 生素 B6 0.3 6 mg、煙酸 2.7 mg、葉酸 91 、泛酸 1.4 mg、 維生素B 12 0·68 pg、生物素6.8 pg、膽驗11 〇 mg、牛績酸 36 mg、肉驗 18 mg、鐵 4.5 mg、磁 36 pg、銅 0.36 mg 及鋅 4.5 mg 〇 藉由將221 g粉末與779 ml水混合得到1 L即飲製劑使配 方復水。以上所定之組合物可改變以適應關於特定成分量 之國家指導。可根據年齡添加足夠量之其他痕量元素(例 如硒、鉻、鉬、氟化物)。 實例2 以下實驗證明以根據本發明之營養配方、補充有根據本 舍明之組成之單獨組份之營養配方及未補充之營養配方健 食受迫初生大鼠的效果。 動物 初產懷孕雌性Long-Evans Hooded大鼠購自 115048.doc 200803760
J nvier(France),於孕期第1〇及u天到達動物養殖實驗 所。將其妹溫及恆濕下單獨飼養直至分挽,且維持在 =12暗:光循環中。隨意提供食物及水。將飼養條件維持 實驗方案之持續時間。分娩後第—天(出生後第2天-PND )將母鼠自生育籠移除,且確定幼鼠性別。隨機指定8 隻雄性幼鼠作為標準小崽,進行撫養。 新生緊迫 將母鼠及其幼鼠分配於兩種飼養條件之一者:1 )母鼠分 離組在PND 2至14暴露於每日母鼠分離180 min時期 (MS),或2)經處理對照組,暴露於每日處理(稱重及Η 處理)彳一並不將母鼠分離(NS)。於9 am,自普通籠中移除 母鼠,且於等待籠中保持3小時分離期(MS母畜)或1 5分鐘 處理期(NS母畜)。將各MS小崽自窩移除,稱重且作為一
組置放於相鄰房間内隔離籠中。將隔離籠保持在32·〇 ± 〇.5°C下。在隔離期結束時,將幼鼠放回其普通籠中,且在 將其與其寄母鼠放在一起前使其在污染草墊上翻滾。相似 地處理自NS組之小崽,但其不經歷3小時分離期,而將其 溫和處理15 min。有5組MS幼鼠及1組NS幼鼠,各組均由8 隻幼鼠組成。 每週一次用清潔草墊替換普通籠中50%之污染草墊。 實驗方案 在PND 15時自寄母鼠完全移除5 MS組中之所有幼鼠, 斷奶且餵食對照飲食或補充飲食1至4之一者。將來自該等 組之各者的幼鼠一起飼養(5隻動物/籠)。NS組與其母親保 115048.doc -14- 200803760 留在一起直至PND 2 1。自PND 15至21,每日監控所有幼 鼠之重量。於PND 21,使來自NS組之幼鼠斷奶且餵食對 照飲食。自此直至PND 36研究結束,單獨飼養所有幼鼠。 自PND 15至PND 36,MS組之幼鼠自斷奶後繼續接受飲 食。每天早晨用新鮮食物替換舊食物,且所有幼鼠隨意接 受其飲食。 飲食 自PND 15至PND 36,以營養適合之半合成飲食(經改質 AIN 93 G)飼養MS組中之動物,該等飲食之組合物於下表1 中展示。補充飲食含有以下功能性成分之一或多者:副乾 酪乳桿菌CNCM 1-2116(於0.8 ml廢培養基中4xl010cfu/100 g 飲食)、0.4 g/100 g 飲食菊糖(Raftiline HP ⑧,Orafti SA, Belgium)、3.6 g/100 g 飲食 GOS(Vivinal ® GOS 10,Borculo Domo Ingredients,The Netherlands)、2 g/100 g飲食二十碳 四烯酸(ARASCO⑧Martek,USA)及2g/100g飲食二十二碳 六烯酸(DHASCO⑧Martek, USA)。對照飲食含有新鮮 MRS而非廢培養基中之益生細菌菌株、乳糖(Fluka,61340) 及增加量之麥芽糊精(Glucidex D12,Roquette Freres, France)而非益生細菌菌株及增加量之可可油及玉米油而非 二十二碳六烯酸及二十碳四烯酸。僅含有根據本發明之組 合物之一種成分的補充飲食同樣含有適當安慰劑成分。 表1飲食組合物 組份 對照 補充1 補充2 補充3 補充4 K-酷蛋白酸鹽(g) 20.00 20.00 20.00 20.00 20.00 玉米澱粉(g) 32.95 32.95 32.95 32.95 32.95 115048.doc 15 200803760 麥芽糊精(g) 20.74 12.58 12.58 12.58 12.58 蔗糖(g) 10.00 10.00 10.00 10.00 ΓΤαοό^ 乳糖(g) 4.26 Raftiline HP (g) 0.42 0.42 Vivinal GOS 10 (g) 12.00 12.00 脂肪混合物(g)(見下文) 7.00 7.00 7.00 7.00 7.00 礦物質混合物(AIN-93-G) 3.50 3.50 3.50 3.50 3.50 維生素混合物(AIN-93-VX) 1.00 1.00 LOO 1.00 1.00 L-半胱胺酸(g) 0.30 0.30 0.30 0.30 0.30 膽鹼氫酒石酸酯DAB 10 0.25 0.25 0.25 0.251 0.25 MRS (ml) 0.80 0.80 0.80 副乾酪乳桿菌CNCM I 2116 (ml) 0.80 0.80 表2脂肪混合物 組份(g/l〇〇 g脂肪混合物) 對照 補充1 補充2 補充3 補充4 大豆油 25.12 26.44 26.44 25.12 25.12 Trisun 80 2.59 2.59 可可油 30.26 27.12 27.12 3026^ 30.26 玉米油 44.63 34.22 34.22 44.63 44.63 ARASCO 4.70 4.70 DHASCO 4.93 4.93 統計 數據以平均值± SEM表示。檢查各組數據的常態性及同 方差性。藉由單因素ANOVA接著藉由費舍爾最小顯著差 異法(Fisher Least Significant Differeilce)(LSD)比較 PND 15 至PND 21之體重、體重指標及脂墊重量數據,以評估處於 各年齡之組之間的差異。藉由重複量測ANOVA及LSD比較 自PND 21之體重及攝取量曲線,以評估組間差異。 結果 結果於圖式中展示。如於圖1中可見,NS組的幼鼠在 PND 1 5與2 1之間持續正常成長,而所有5個MS組的幼鼠體 重下降直至PND 1 7,接著該組因餵食根據本發明之組合物 115048.doc -16- 200803760 (補充飲食1)而恢復成長,且展示最有效之趕上成長。自 PND 21至36,㈣勢因該組接受根據本發明之組合物而加 速,且在PND 36時達到與>^組極為相似之體重(圖2)。藉 由比較可見,餵食對照飲食(亦及與^^組之相同飲食 MS組到PND 36時達到顯著較低體重。自圖2亦可見,接受 補充飲食4(僅益生素)2MS组亦達到與對照]^8組相當之最 終重星。其原因可見於圖3,圖3展示此組之食物攝取量在 PND 21至36—直高於所有其他組。然而,此較高卡路里攝 取K似乎並不直接反映成長進度。藉由比較,接受補充飲 食1之MS組比接受補充飲食4iMS組具有較低食物攝取 ϊ,且具有與包括對照飲食之其他組相當之食物攝取量。 此外,自圖4及5可見,由接受補充飲食丨之…^組所展示 之趕上成長進度與體重指標或總身體脂肪質量之增加無 關,雖然該等參數與非受迫組之參數相當。吾人總結如 下’含有根據本發明之成分之組合的營養配方可有效促進 因身體或精神緊迫而成長進度延緩之幼年哺乳動物之趕上 成長進度,及因為單獨給與之成分的作用總和小於組合給 與之作用’因此該組合為增效。此外,趕上成長進度與不 成比例之體重指標增加無關,因此應不增加隨後生活之肥 胖風險。 【圖式簡單說明】 圖1展示自出生後(PND)l 5-21天接受不同飲食之6組大鼠 的體重演變。 圖2展示自pND 21_36天與圖1相同組大鼠的體重演變。 115048.doc 17 200803760 圖3展示自PND 2卜36天相同組大鼠的食物攝取量。 圖4展示PND 36天時六組大鼠的體重指標(g/cm2)。 圖5展示PND 36天時六組大鼠之副睾及腹膜後脂墊之重 量(g)。 115048.doc 18-
Claims (1)
- 200803760 十、申請專利範圍: 1· 一種用於促進趕上成長進度之營養配方,其包含一含有 脂肪酸之脂質源、該配方中脂肪酸之至少〇·〇1%之量的 η3長鏈多元不飽和脂肪酸(LC_puFA)、每克配方〇·⑻w “ 至〇·05克之量的益生纖維及每克配方10^1011 cfu之量的 盈生細菌菌株。 2. 如請求項1之配方,其進一步包含該配方中之脂肪酸之 至少0.01%之量的n6 LC-PUFA。 3. 如請求項丨或2之配方,其中該益生細菌菌株為乳酸桿菌 屬(Lactobacillus) 〇 4·如請求項3之配方,其中該乳酸桿菌屬為副乾酪乳酸桿 菌似ez.)CNCM 1-2116。 5 ·如前述請求項中任一項之配方,其中該益生纖維之量每 克配方0.02至〇·〇5克。 6·如前述請求項中任一項之配方,其中該益生纖維為果募 醣、菊糖、半乳寡醣、阿拉伯膠或其混合物。 7 ·如請求項6之配方,其中該益生纖維為40至60%阿拉伯 膝、10至20%菊糖及30至40%果寡醣之混合物。 ^ 8·如前述請求項中任一項之配方,其中n6 LC-PUFA與η3 • LC-PUFA之比為 1:2至 8:1。 9·如請求項2至8中任一項之配方,其中n3 LC-PUFA為二十 —六稀酸。 10.如前述請求項中任一項之配方,其中n3 LC-PUFA為二十 ^六稀酸。 115048.doc 200803760 11 ·如前述請求項中任一項之配方,其為兒科營養配方。 12· —種n3長鏈多元不飽和脂肪酸(LC-PUFA)、益生纖維及 益生細菌菌株用於製造供促進患病及恢復期幼年哺乳動 物趕上成長進度之營養配方或藥物的用途。 13·如請求項12之用途,其中該配方包含一含有脂肪酸之脂 質源,且n3 LC-PUFA之量為該脂質源中脂肪酸之至少 0.01〇/〇 〇 14·如請求項12或π之用途,其中該營養配方或藥物進一步 包含 n6 LC-PUFA。 15·如請求項14之用途,其中該n6 LC-PUFA之存在量為脂質 源中脂肪酸之至少〇.〇1〇/0。 16·如請求項12至15中任一項之用途,其中該益生纖維之量 為每克配方0.0001至0.05克。 17·如請求項12至16中任一項之用途,其中該益生細菌菌株 之量為每克配方之1〇3 - 1011 cfu。 18·如請求項12至17中任一項之用途,其中該益生細菌菌株 為乳酸桿菌屬。 19·如請求項18之用途,其中該乳酸桿菌屬為副乾酪乳酸桿 菌 CNCM 1-2116。 20·如請求項12至19中任一項之用途,其中該益生纖維之量 為每克配方0.02至0.05克。 21·如請求項12至20中任一項之用途,其中該益生纖維為果 募醣、菊糖、半乳寡醣、阿拉伯膠或其混合物。 22.如請求項21之用途,其中該益生纖維為40至60%阿拉伯 115048.doc 200803760 膠、10至20%菊糖及30至40%果寡醣之混合物。 23. 如請求項12至22中任一項之用途,其中n6 LC-PUFA與n3 LC-PUFA之比為 1:2至 8:1。 24. 如請求項12至23中任一項之用途,其中n3 LC-PUFA為二 十二碳六稀酸。 25. 如請求項14至24中任一項之用途,其中n6 LC-PUFA為二 十碳四烯酸。 115048.doc 200803760 七、指定代表圖: (一) 本案指定代表圖為:第(1)圖。 (二) 本代表圖之元件符號簡單說明: (無元件符號說明) 八、本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無) 115048.doc
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05109248 | 2005-10-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200803760A true TW200803760A (en) | 2008-01-16 |
TWI404508B TWI404508B (zh) | 2013-08-11 |
Family
ID=35709026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095137247A TWI404508B (zh) | 2005-10-05 | 2006-10-05 | 用於促進趕上成長進度之營養配方 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9144250B2 (zh) |
EP (1) | EP1940248B1 (zh) |
CN (1) | CN101299934B (zh) |
AT (1) | ATE451845T1 (zh) |
AU (1) | AU2006298720C1 (zh) |
BR (1) | BRPI0616899A2 (zh) |
CA (1) | CA2624921C (zh) |
DE (1) | DE602006011195D1 (zh) |
ES (1) | ES2334943T3 (zh) |
MY (1) | MY143654A (zh) |
PL (1) | PL1940248T3 (zh) |
PT (1) | PT1940248E (zh) |
RU (1) | RU2445360C2 (zh) |
TW (1) | TWI404508B (zh) |
WO (1) | WO2007039596A1 (zh) |
ZA (1) | ZA200803769B (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8075934B2 (en) * | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
US20080254166A1 (en) * | 2007-01-25 | 2008-10-16 | Potter Susan M | Food Additives Containing Combinations of Prebiotics and Probiotics |
JP2009102292A (ja) * | 2007-04-27 | 2009-05-14 | Chiba Prefecture | ストレス抑制剤 |
SI2190304T1 (sl) | 2007-09-17 | 2012-04-30 | Nutricia Nv | Prehranska formulacija z visoko energijsko vsebnostjo |
MX2010003090A (es) * | 2007-09-21 | 2010-04-09 | Kerry Group Services Int Ltd | Una composicion de probiotico. |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
ES2384510T3 (es) * | 2008-03-27 | 2012-07-06 | Morinaga Milk Industry Co., Ltd. | Bebida ácida de bacterias de ácido láctico y método para producir la bebida ácida de bacterias de ácido láctico |
EP2110028A1 (en) * | 2008-04-15 | 2009-10-21 | Nestec S.A. | Bifidobacterium longum and hippocampal BDNF expression |
US20100074870A1 (en) * | 2008-09-19 | 2010-03-25 | Bristol-Myers Squibb Company | Probiotic infant products |
PL2413952T3 (pl) | 2009-04-03 | 2017-08-31 | Nestec S.A. | Polepszenie promowania zdrowego doganiania wzrostu |
ES2559008T3 (es) * | 2009-05-11 | 2016-02-10 | Nestec S.A. | Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios |
WO2010134800A1 (en) | 2009-05-19 | 2010-11-25 | N.V. Nutricia | Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution |
EP2258218A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
EP2258217A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Children |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
AU2010277582A1 (en) * | 2009-07-31 | 2012-02-02 | Nestec S.A. | Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients |
JP6006117B2 (ja) | 2009-11-12 | 2016-10-12 | ネステク ソシエテ アノニム | 腸内微生物叢バランス及び健康を促進するための栄養組成物 |
WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
IT1405395B1 (it) * | 2010-08-05 | 2014-01-10 | Proge Farm Srl | Composizioni di probiotici e oli e loro uso. |
WO2012050434A1 (en) * | 2010-10-15 | 2012-04-19 | N.V. Nutricia | Dairy based smoothie for stimulating growth in children |
US9375028B2 (en) | 2010-12-09 | 2016-06-28 | Mead Johnson Nutrition Company | Compositions and methods for nutrient delivery |
US20130095204A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Nutritional phytonutrient compositions |
WO2015065193A1 (en) | 2013-11-01 | 2015-05-07 | N.V. Nutricia | Lipid composition for improving body composition during catch-up growth |
CN106455653A (zh) | 2014-03-26 | 2017-02-22 | 雅培公司 | 营养补充粉 |
ES2742522T3 (es) | 2015-10-15 | 2020-02-14 | Nutricia Nv | Fórmulas para lactantes con arquitectura lipídica especial para promover el crecimiento saludable |
WO2017151540A1 (en) | 2016-02-29 | 2017-09-08 | Abbott Laboratories | Nutritional supplement powder |
EP3426062A1 (en) * | 2016-03-10 | 2019-01-16 | Enzymotec Ltd. | Lipid compositions and uses thereof |
RU2748025C2 (ru) | 2016-12-09 | 2021-05-19 | Н.В. Нютрисиа | Питательный состав для улучшения клеточных мембран |
MX2022010647A (es) * | 2020-02-27 | 2022-09-23 | Abbott Lab | Metodos para mejorar la salud osea. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1191828C (zh) * | 1997-03-27 | 2005-03-09 | 布里斯托尔-迈尔斯斯奎布公司 | 二十二碳六烯酸和花生四烯酸促进不足月婴儿生长的用途 |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
US6495599B2 (en) * | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
US20020044988A1 (en) * | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
GB0308104D0 (en) * | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
WO2004112509A2 (en) | 2003-06-23 | 2004-12-29 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
WO2005063050A1 (en) * | 2003-12-19 | 2005-07-14 | Abbott Laboratories | Method of increasing lean body mass and reducing body fat mass in infants |
-
2006
- 2006-10-02 CN CN2006800413205A patent/CN101299934B/zh not_active Expired - Fee Related
- 2006-10-02 ES ES06806927T patent/ES2334943T3/es active Active
- 2006-10-02 BR BRPI0616899-0A patent/BRPI0616899A2/pt not_active IP Right Cessation
- 2006-10-02 PL PL06806927T patent/PL1940248T3/pl unknown
- 2006-10-02 CA CA2624921A patent/CA2624921C/en not_active Expired - Fee Related
- 2006-10-02 EP EP06806927A patent/EP1940248B1/en not_active Revoked
- 2006-10-02 PT PT06806927T patent/PT1940248E/pt unknown
- 2006-10-02 US US12/089,423 patent/US9144250B2/en not_active Expired - Fee Related
- 2006-10-02 WO PCT/EP2006/066970 patent/WO2007039596A1/en active Application Filing
- 2006-10-02 DE DE602006011195T patent/DE602006011195D1/de active Active
- 2006-10-02 RU RU2008117401/10A patent/RU2445360C2/ru not_active IP Right Cessation
- 2006-10-02 AU AU2006298720A patent/AU2006298720C1/en not_active Ceased
- 2006-10-02 AT AT06806927T patent/ATE451845T1/de not_active IP Right Cessation
- 2006-10-05 TW TW095137247A patent/TWI404508B/zh not_active IP Right Cessation
- 2006-10-06 MY MYPI20080980A patent/MY143654A/en unknown
-
2008
- 2008-04-30 ZA ZA200803769A patent/ZA200803769B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2624921C (en) | 2012-07-10 |
AU2006298720A1 (en) | 2007-04-12 |
PT1940248E (pt) | 2010-01-26 |
CN101299934B (zh) | 2012-08-08 |
DE602006011195D1 (de) | 2010-01-28 |
AU2006298720C1 (en) | 2013-03-14 |
US20080254012A1 (en) | 2008-10-16 |
CA2624921A1 (en) | 2007-04-12 |
RU2008117401A (ru) | 2009-11-10 |
EP1940248A1 (en) | 2008-07-09 |
ATE451845T1 (de) | 2010-01-15 |
BRPI0616899A2 (pt) | 2011-07-05 |
PL1940248T3 (pl) | 2010-05-31 |
AU2006298720B2 (en) | 2012-07-19 |
ES2334943T3 (es) | 2010-03-17 |
US9144250B2 (en) | 2015-09-29 |
CN101299934A (zh) | 2008-11-05 |
TWI404508B (zh) | 2013-08-11 |
EP1940248B1 (en) | 2009-12-16 |
WO2007039596A1 (en) | 2007-04-12 |
RU2445360C2 (ru) | 2012-03-20 |
ZA200803769B (en) | 2009-07-29 |
MY143654A (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI404508B (zh) | 用於促進趕上成長進度之營養配方 | |
ES2560023T3 (es) | Composición para su uso para incrementar la sensibilidad a la insulina y / o para reducir la resistencia a la insulina | |
US9591872B2 (en) | Nutritional composition for children with reflux, colic and/or constipation | |
US20120107279A1 (en) | Prevention and treatment of rotavirus diarrhoea | |
ES2802985T3 (es) | Vitamina B2 y mioinositol para el tratamiento y la prevención de la diabetes gestacional | |
TW200946033A (en) | Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation | |
RU2685187C2 (ru) | Жидкая композиция обогатителя молока с относительно высоким содержанием липидов | |
CN111227044A (zh) | 一种乳制品、其制备方法及医药应用 | |
AU2014356449B2 (en) | Age-tailored nutritional compositions with a varying protein content | |
JP2016505024A5 (zh) | ||
TW201538086A (zh) | 用於健康成長與發展之具有乳類肽之小兒營養組成物 | |
US20230012011A1 (en) | Mixture of hmos for improving the microbiota of pregnant women | |
TW201532529A (zh) | 含有熊果酸之神經性成分的營養組成物及彼之用途 | |
US9345727B2 (en) | Nutritional compositions containing a peptide component and uses thereof | |
US20220409645A1 (en) | Compositions for use in the reduction of pain and/or perception of pain in infants and young children | |
Falcão et al. | Infant Formulas: A Long Story | |
RU2808973C2 (ru) | Питательная композиция для младенцев, предназначенная для применения с целью улучшения созревания поджелудочной железы и биосинтеза инсулина | |
US20140170265A1 (en) | Infant formula cubes | |
BR112021004949A2 (pt) | composições nutricionais, seu uso na redução do estresse metabólico e método para reduzir o estresse metabólico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |